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Abstract 
Histopathologists are critical in the diagnosis of hereditary gastrointestinal tumours.  This is 
increasingly important as genetic testing becomes more available and the benefits of anti-
cancer surveillance in those at increased risk are realised.  Cancer genetics services should 
include pathologists and be organised on multidisciplinary team lines.  Hereditary cancer 
syndromes predispose to tumours throughout the GI tract.  Lynch syndrome is the most 
prevalent hereditary GI cancer condition, responsible for ~3.3% of all colorectal as well as 
other GI and extra-intestinal cancers.  Tumour tests to diagnose Lynch syndrome are 
important in guiding genetic testing, and can be used systematically to screen cancers for 
the condition.  Familial adenomatous polyposis and all the other forms of hereditary 
polyposis put together account for <1% of all colorectal cancer.  However, the histological 
distinction of the various polyposes, including type, site and numbers of polyps is crucial in 
informing genetic testing. 
Key words 
Genetic Predisposition to 
Disease 
Colon 
Rectum 
Adenocarcinoma 
Adenoma 
Polyps 
Gastrointestinal 
neoplasms 
Biopsy 
DNA mismatch repair 
Immunohistochemistry 
Microsatellite instability 
Quality control 
Lynch syndrome 
Adenomatous polyposis 
coli 
Peutz-Jeghers Syndrome 
Juvenile Polyposis 
Syndrome 
Hereditary Mixed 
Polyposis Syndrome 
Cowden Syndrome 
Hamartoma Syndrome, 
multiple 
  
1. Context 
A fundamental part of the clinical and laboratory examination of a patient with a gastrointestinal 
tumour is the histopathology.  It is absolutely critical in achieving the diagnosis.  This is especially 
the case where that diagnosis includes a possible hereditary predisposition, because this has 
implications for both the patient, the relatives, and unrelated individuals who happen to have the 
same underlying genetic mutation. 
Phenotype is defined as “the set of observable characteristics of an individual resulting from the 
interaction of its genotype with the environment” and, therefore, is what you are: a function of your 
genes and the environment they find themselves in.  Histopathology is therefore crucial in defining 
an individual tumour phenotype, informing in turn genetic investigations and the interpretation of 
genetic variation found in that patient.  The genome, an individual’s complete DNA sequence, is 
now accessible.  About one quarter of all the 21,000 or so human genes have an associated 
clinical phenotype.  The protein-coding parts of all genes, constituting about 2% of the genome, is 
called the exome, and clinical testing of the exome is already available.  Hence, as medicine 
moves from a genetic, single gene, era into the genomic era, so it becomes increasingly important 
to define phenotype.  Dysmorphism, that is abnormalities in gross morphologic development, is an 
important feature of many genetic conditions and why clinical geneticists are highly trained in 
recognising such features.  While some cancer genetic conditions certainly do have associated 
dysmorphic features, the histopathologist can be thought of as the cancer geneticist’s 
dysmorphologist – histopathologists having the necessary expertise, skills and tools to define 
abnormalities in tumours at the macroscopic, microscopic and molecular level, working where 
necessary with colleagues in related disciplines. 
Cancer genetics now accounts for more than half of all the clinical genetics care provided in the 
UK, and the role of histopathology in the provision of such services is thus proportionately 
important.  We would strongly urge colleagues in genetics, both clinical and laboratory, to work 
closely with histopathologists, and vice versa: the model of the multidisciplinary team will be 
familiar as best practice.  The importance of critically utilizing key information in pathology reports 
is stressed to those who attend e.g. the UK national cancer genetics courses for doctors, 
counselors and laboratory scientists, as is asking for histopathological review of multiple samples 
from family members in complex cases.  However, whilst the mainstay of clinical cancer genetics 
has classically been the ‘family history’, it is becoming apparent that laboratory tests on tumours 
have better specificity and sensitivity than family history at finding those who harbour inherited 
mutations.  So, as such tests become cheaper to perform, the identification of patients with 
hereditary predisposition is moving towards systematic screening for biomarkers in incident cases.  
Cancer genetic conditions generally predispose to tumours of various types and at more than one 
site.  Whilst histopathologists will usually be presented with tissue from a specific organ, we have 
decided to take a condition rather than organ-based approach and concentrate on those conditions 
which are relatively common or warrant careful differentiation on histological grounds. 
It should be borne in mind that many syndromes are multi-system and predispose to more than just 
GI tumours.  Also, that this review is not exhaustive and does not need to be, as nowadays there 
are many online sources of information regarding hereditary cancer, such as the family cancer 
database (FaCD: http://www.familialcancerdatabase.nl/).  Here, the features of known syndromes 
may be browsed, help can be given with identifying a syndrome from tumour types and symptoms, 
or searches on a word or gene can be performed.  We recommend that the reader refer to the 
relevant sections of this resource in conjunction with this review.  Online Mendelian Inheritance in 
Man (OMIM; http://www.omim.org/) is another valuable resource: for each gene and phenotype 
there are OMIM entries.  The Oxford Desk Reference: Clinical Genetics has sections on GI cancer 
and associated syndromes.[1] 
2. GI-cancer associated genetic conditions 
These can be divided into polyposes, in which an excess of polyps is seen, and those in which 
there is no obvious excess, such as Lynch syndrome and hereditary diffuse gastric cancer. 
2.1 Lynch Syndrome 
Lynch syndrome (LS) is the most prevalent single-gene disorder predisposing to colorectal cancer.  
It is caused by constitutional mutations affecting one of four DNA mismatch repair (MMR) genes, 
specifically MSH2, MLH1, MSH6 or PMS2.  In Denmark, where systematic testing for LS is now 
carried out on all CRC, approximately 3.3% are now known to be due to LS, implying a prevalence 
of at least 1:500.  The main cancers LS predisposes to are CRC and endometrial cancer, but a 
wide spectrum of associated tumours is now recognised, including from the GI tract, stomach, 
small bowel, hepatobiliary tract and, possibly, pancreatic cancer, but also upper urinary tract, 
ovaries, brain, prostate and breast.[2]  The average age of onset of CRC is approximately 42y, but 
varies with the underlying gene, as does the spectrum of associated cancers.  An individual with 
LS has a high, but not inevitable risk of cancer.  Current best estimates of risk in mutation carriers 
to age 70y of any LS-associated cancer are ~60% in men and ~70% in women.  Both MSH2 and 
MLH1 are associated with higher risks and younger onset, with MSH6 and PMS2 conferring lower 
risks and at older age, while MSH6 confers a relatively greater risk of endometrial 
cancer.[2,3](Table 1) 
Table 1.  Major cancer risks in Lynch syndrome, by underlying gene. 
In the case of MSH2 there is an additional mechanism of disease in that large deletions in an 
adjacent gene, EPCAM (whose product is expressed in gut mucosal brush border) can affect 
MSH2 expression in one of two ways.  With deletions encompassing both EPCAM and MSH2 the 
associated phenotype is indistinguishable from mutations of any sort involving MSH2 alone.  
However, deletions only involving EPCAM can lead to read through of mRNA into MSH2, resulting 
in expression of a non-functional protein and methylation of the MSH2 promoter, which prevents 
any normal MSH2 being produced.  Curiously, the associated phenotype is of both large and small 
bowel cancers, but not endometrial cancer, which may reflect the tissue expression pattern of 
EPCAM. 
However, because of the tendency in LS to earlier onset and somewhat more survivable cancers, 
some individuals can and often do develop two or more cancers.  The variety of associated tumour 
types also means that a possible diagnosis of LS may not be immediately obvious to clinicians (or 
patients) either in an individual or family.  Hence, it is important for the pathologist to be aware of 
such possible combinations and alert colleagues to them, if necessary after appropriate 
investigation and discussion within an MDT that includes cancer genetics input. 
The cells of individuals with LS have proficient DNA mismatch repair (MMR), but if a somatic 
mutation occurs in the other copy of the respective gene then MMR deficiency results in that cell.  
One consequence of this is that the genome of such cells starts to accumulate innumerable small 
mutations, particularly, but by no means exclusively in repetitive stretches of DNA, called 
microsatellites, resulting in the phenomenon of microsatellite instability (MSI).  Another is that the 
loss of MMR function is manifest as abnormal or lost expression of the affected MMR protein (and 
often its binding partner), readily detectable by immunohistochemistry (IHC).  Concomitantly, and 
probably because MMR is necessary for chromosomal recombination to occur, such cells then 
stop accumulating large scale chromosomal defects, classically manifest as chromosomal 
instability, classically typified by loss of heterozygosity (LOH).  Hence, tumours which have lost 
MMR not only have MSI and abnormal MMR expression, but are typically near-diploid. 
It has been suggested that the raised mutation rate in MMR deficient cells is the Darwinian 
selectable advantage driving such tumours.  However, while the phenomenon of MSI is certainly 
diagnostically useful there is good reason to believe that it may just be a paraphenomenon, albeit 
diagnostically useful: that the mutation rate in cells is not limiting and that it is a reduction in MMR-
triggered apotosis which is the driver.  It is also suggested that the CRC in LS develop much faster 
than in the general population, with the high frequency of interval cancers despite frequent (2 
yearly) colonoscopy being cited as evidence.  However, this presupposes that such cancers all 
arise in adenomas and the role of the serrated lesion in LS may be more significant than has been 
previously recognised. 
2.1.1  Muir-Torre syndrome and LS 
Muir-Torre syndrome (MTS) is the occurrence in the same individual of keratoacanthomas or 
sebaceous adenomas/carcinomas with an internal cancer and is common in LS, more often, but 
not exclusively associated with mutations in MSH2.  However, LS is probably not the only cause of 
MTS. 
2.1.2  Colorectal cancer pathology in LS 
Colorectal cancers (CRC) in LS have a skewed anatomical distribution, being more likely to occur 
in the colon than rectum compared to sporadic CRC.  It is important to understand, however, that 
approximately 12% of colon cancers have sporadic loss of MMR and hence MSI, but MSI in 
younger CRC is more likely due to LS.  Hence, most MSI in colon cancers is sporadic, but this 
proportion is highly age dependent: about 25% of CRC at 35y are due to LS, reducing to 4% at 55y 
and 3% ≥60y, whereas the rate of sporadic MSI is 2% between 35-55y, then rises to 12% at 
70y.[4] 
LS CRCs are more likely to have mucinous or poorly differentiated histology, exhibit high grade 
(poor) differentiation, and have tumour infiltrating lymphocytes, but these features are by no means 
absolute.[5]  In particular, while in the past it has been commented that CRCs in LS show a 
marked peritumoural Crohns-like reaction of lymphoid follicles, it actually turns out that this is more 
common in CRC without MSI.[6]  For a given stage, however, LS CRC do appear to have improved 
survival, for reasons that may include better response to chemotherapy, different host immune 
response, younger age of the patient and reduced propensity to metastasize, but exactly why 
remains unclear.   
Adenomas in LS tend to be larger, villous, with high grade dysplasia and undoubtedly cancers 
arise in them.  A smaller proportion of adenomas than carcinomas are found to have lost MMR in 
LS, but it is higher than in the general population, so the significance of finding it in an adenoma is 
greater.  It is variable as to when in an individual tumour’s development that it loses MMR function, 
and it is not necessarily at the initiation of the lesion.  However, there are a number of lines of 
evidence suggesting that serrated lesions, such as sessile serrated lesions/polyps/adenomas and 
serrated adenomas, play a greater role in the pathogenesis of CRC in LS than hitherto suspected.  
Firstly, It has been found that in the large bowel mucosa of individuals with LS about one crypt per 
cm2 has deficient MMR.[7]  So, adult LS patients have hundreds of aberrant crypts, but they only 
develop a modest number of CRC, if any, which does not fit with the idea of rapid and inevitable 
progression of adenomas into carcinomas in LS.  Secondly, the reduction in mortality consequent 
upon intensive colonoscopic surveillance in LS is a function of downstaging rather than adenoma 
removal: approximately 70% of the CRC detected in LS patients undergoing colonoscopy are 
Dukes’ A, compared to about 17% in LS patients not undergoing surveillance.[8]  Thirdly, serrated 
lesions are now known to give rise to CRC with MSI.  And, fourthly, the CaPP2 trial of aspirin 
chemoprophylaxis in LS showed no reduction in the numbers of adenomas in those on the drug 
whereas a very significant reduction in CRCs was seen several years after cessation of aspirin 
treatment, suggesting that whatever premalignant lesion aspirin is acting upon takes time to 
develop into a cancer and may not be adenomatous. 
2.1.3  Tumour tests in LS: MSI 
Microsatellites are stretches of short repeat sequences in DNA.  In a cell in which MMR is lost such 
repeats undergo contraction or expansion mutations, which are evident when they are compared to 
the normal constitutional DNA of the individual.  Originally, dinucleotide repeats, e.g. (CA)n were 
used, but it has since become evident that mononucleotide repeats, e.g. (A)n or “polyA” are more 
sensitive markers.  Instability at a single microsatellite does not necessarily confer a diagnosis of 
microsatellite instability (MSI), usually this is dependent on finding instability at, say, 2 out of 5 
markers.  However, it has to be borne in mind that the markers in common use were originally 
used to find MSI in colon cancers, and when looking at cancers at other sites, including e.g. 
rectum, endometrium etc., they are less sensitive.  They are also less sensitive in benign tumours, 
e.g. colorectal adenomas, and less sensitive when the underlying genetic defect is in MSH6 or 
PMS2.  Sensitivity has also been shown to depend on the proportion of tumour DNA being tested.  
Laser microdissection is not feasible for routine diagnostics, but macrodissection definitely 
improves test performance.  If endeavouring to get a result with a small biopsy, 
immunohistochemistry is the better option.[9] 
Specificity is a major issue, as a proportion of all sporadic tumours show MSI.  In the colon about 
12% of adenocarcinomas show MSI, of which about 1-in-4 will be due to LS, the rest sporadic.  In 
contrast, rectal cancers rarely exhibit MSI, but when they do it usually indicates LS.[10]  A similar 
proportion of gastric and other GI adenocarcinomas also exhibit MSI, so finding MSI is not in itself 
sufficient evidence of LS, rather the whole setting of age of onset, tumour type, how other relatives 
may have been affected, all need to be taken into consideration.  Hence, the strong 
recommendation for MDT working in which genetics input is included.  While finding MSI does not 
necessarily equate to LS, not finding MSI, otherwise known as microsatellite stability (MSS) is 
good to excellent evidence that LS did not cause that tumour, but it has to be considered that some 
tumours, e.g. due to MSH6 may not show MSI in >1 of 5 markers (so MSI-L, see below) and Lynch 
patients will occasionally suffer from sporadic tumours.  Lastly, the MSI typically seen in LS 
cancers is called MSI-high (MSI-H), where a good proportion of markers are unstable, in contrast 
to MSI-low (MSI-L) which is instability in around 1 of 5 markers: MSI-L, as described in sporadic 
tumours often of serrated lineage. 
2.1.4  Tumour tests in LS: BRAF & MLH1 promoter methylation 
As a way to determine if a colon cancer with MSI is sporadic, it is possible to test for the presence 
of a specific oncogene mutation in tumour DNA: BRAF p.Val600Glu or “V600E”.  If such a mutation 
is present then the tumour is sporadic in origin.  However, while LS colon cancers do not acquire 
this mutation, a proportion of sporadic tumours do not either.  Early estimates were that ~15% of 
sporadic colon cancers with MSI did not have BRAF V600E, but the true proportion is looking to be 
lower, perhaps 5%.  The significance of BRAF V600E in tumours at other sites is less clear.  In 
endometrial cancers, for example, it is of no diagnostic use.  Recently, detection of BRAF V600E 
has been described using IHC, although its reliability has been questioned.[11] 
Sporadic colon cancers with MSI have usually, but not invariably, lost MMR because of 
hypermethylation of the promoter of MLH1 on both chromosomes turning off gene expression, 
often as part of a more general cancer genome methylation phenomenon.  It is possible to test for 
methylation of MLH1 and it theoretically addresses the issue of lack of specificity of the BRAF test.  
However, a small proportion, perhaps 1% of patients with a CRC with MSI harbour constitutional 
methylation of MLH1, giving them an unusual form of LS and cancers that appear to be sporadic, 
but are clearly not when their constitutional DNA is compared with that from their tumour.  Most 
such patients with this type of so-called epimutation are not at risk of passing it on to offspring, 
however, it has been found that in a small proportion there is a risk of transmission.  This may be 
related to chromosomal rearrangements involving the MLH1 region causing secondary 
methylation, not unlike the large mutations involving EPCAM which cause methylation and so lack 
of expression of MSH2.  Hence, this only goes to show that no test is 100% sensitive or specific, 
and all possibilities must be borne in mind as part of an MDT discussion. 
2.1.5  Tumour tests in LS: MMR immunohistochemistry 
Mismatch repair immunohistochemistry (MMR IHC) is often performed on any suspected LS 
tumour, including biopsies.[9]  It will be appreciated that the technical performance of MMR IHC 
can vary widely depending on fixation, antigen retrieval, primary antibody and staining platform.  It 
is therefore most important that laboratories participate in EQA schemes such as UK NEQAS ICC 
(http://www.ukneqasicc.ucl.ac.uk/) or Nordic Quality Control (NordiQC; http://www.nordiqc.org/).  
UK NEQAS ICC has issued guidelines.[12]  A good gradient of expression should be demonstrated 
in crypts, fading out towards the lumen, and stromal / lymphoid cells should be positively 
stained.(Fig. 1)  An important factor in achieving good results is to use normal colon or appendix as 
controls and not tonsil, in the lymphoid follicles of which MMR proteins are generally expressed at 
a higher level than in crypts.  Hence, adequate staining density in tonsil may mean that mucosal 
staining is weak.  In addition, all efforts should be made to eliminate inappropriate and non-specific 
staining. 
Fig. 1 Normal appendix 
Tumour cells will have either stronger expression (DNA repair is upregulated in cells with increased 
turnover) or abnormal expression.  Usually such abnormal expression is manifest as loss of 
expression, but it can also take more subtle forms, such as loss of nuclear, but gain of cytoplasmic 
staining.(Fig. 2)  In a small proportion of LS tumours, expression may be patchy / weak and not 
uniform within a tumour.  However, MMR protein IHC is particularly fixation-dependent as poorly 
fixed tumours (a common problem for CRC) show a lack of MMR immunostaining in tumour cells 
and stromal / lymphoid cells, often affecting all four MMR proteins similarly. To decide whether the 
patchy / weak staining pattern is a fixation artefact or true biology it helps greatly to have stained 
for all four MMR proteins, MSH2, MSH6, MLH1 and PMS2.  If all show patchy expression, in both 
tumour and stromal / lymphoid cells, then fixation artefact is likely. 
Fig. 2  Colorectal cancers showing loss of MLH1 and MSH2  
 
 
It is also valuable to test all four markers because of the clues this can give to the underlying 
genetic defect.  MSH2 and MSH6 proteins work as a heterodimer, mutSα, to detect a mismatch in 
DNA and then recruit the heterodimer mutLα, composed of MLH1 and PMS2, to resolve the defect.  
So, with an underlying mutation in the MSH2 gene, MSH2 protein expression is commonly lost 
together with MSH6.  However, MSH6 expression can be retained or abnormal and show shifts 
from the nuclear to cytoplasmic compartments.  Similarly, mutations in MSH6 typically cause 
abnormality of MSH6 with retained (or slightly reduced) expression of MSH2.  However, a 
missense mutation has recently been described in MSH6, involving its MSH2 binding site, and is 
thus associated with loss of MSH2 but retention of MSH6 expression in tumours, so this 
relationship of abnormal expression always being directly related to the underlying genetic defect is 
not hard and fast.  Similarly, loss of MLH1 expression due to underlying MLH1 mutation (or 
epimutation/methylation) is often associated with loss of PMS2 expression, but loss of this 
combination is rather less often associated with an underlying PMS2 mutation.  In patients with 
loss of PMS2 expression alone, however, it is well worthwhile to test for mutations in PMS2. 
Very usefully, data has recently been presented on the underlying causes associated with patterns 
of MMR IHC in colorectal and endometrial tumours with MSI found in the setting of families in 
genetics clinics.[13] (Table 2)  This also shows that by no means are all mutations necessarily 
associated with loss or abnormality of the corresponding protein.[13,14]  Hence, patterns of MMR 
IHC abnormality are a guide to, but not an absolute indicator of the underlying genetic defect.   
Table 2.  Underlying causes of microsatellite instability in colorectal and endometrial cancers in 
genetics clinic patients, by associated pattern of MMR IHC abnormality. 
 
Comprehensive data on consistency of IHC abnormality associated with specific mutations is 
lacking, but in the authors’ experience it is variable: some mutations are associated with abnormal 
expression in perhaps 50% of tumours in a family, whereas with others it is 100%.  In addition, in 
1-2% of tumours that are tested, unusual combinations of abnormality may be seen, such as loss 
of MSH2 and PMS2, or three proteins, for reasons which are unclear (although some of the MMR 
genes contain coding microsatellites which may bias them to somatic mutations in cells with 
deficient MMR).  Thus, pathologists should be aware that MMR IHC, like all tests, has finite 
sensitivity and specificity and some complex cases provide challenges in interpretation. 
2.1.6  Tumour tests in LS: Systematic testing of incident cases 
Ascertainment of LS by means of family history has a number of limitations, and suffers from 
considerable insensitivity and lack of specificity.  Given that LS cancers are a cause of avoidable 
early onset death there is a very strong case for systematic testing of incident cancers to find the 
condition, the health economics of which has now been firmly established.[15]  Because of this, 
and the prognostic and predictive information that detection of abnormal MMR can confer, the 
Royal College of Pathologists Minimum Dataset (2014) for Colorectal Cancer now states that 
testing of all CRC up to age 50 for deficient MMR is required (for accredited services in the UK this 
is thus now effectively mandatory), and while the case is similarly made for testing all CRC 
between 50 and 70 y, testing is optional in this age range until commissioning is established.[16]  
Systematic testing of all CRC has been carried out for two years in Denmark, regardless of age, 
showing that ~3.3% of all CRC are due to LS.  However, health economic analyses from both The 
Netherlands and the UK indicate that testing of CRC over 70y would not be cost-effective. 
2.1.7  Constitutional Mismatch Repair Disorder (CMMR-D) 
Individuals who inherit mutations in both copies of an MMR gene develop a condition known as 
Constitutional Mismatch Repair Disorder (CMMR-D).  In its most severe form this is manifest as a 
propensity to brain cancer (mostly high-grade gliomas, but also includes supratentorial primitive 
neuroectodermal tumours and medulloblastomas), leukaemia and lymphoma with death by the age 
of 12 y.[17]  The development of colorectal adenomas, sometimes amounting to polyposis, is also 
seen, as are cutaneous café-au-lait spots and other signs hitherto associated with NF1, such as 
freckling, Lisch nodules and neurofibromas.  It is now appreciated that the first described cases, in 
consanguineous families, were this severe because the underlying mutations were in MSH2 and 
MLH1.  As cases due to MSH6 and PMS2 have been ascertained it is evident that CRC, small 
bowel and other LS-associated cancers develop in teenage, with individuals surviving into their 
third decade or beyond. 
All cells in individuals with CMMR-D, tumours included, show loss of the respective MMR protein.  
This is diagnostic and another reason why all four MMR proteins should be assessed.[18] 
CMMR-D shows recessive inheritance in the peculiar circumstance of the mutation carriers 
themselves exhibiting LS, a dominant condition, in analogous fashion to individuals with one 
BRCA2 mutation having familial breast-ovarian cancer, while those with two BRCA2 mutations 
have Fanconi anaemia, complementation group D1.  Turcot’s syndrome, characterised by brain 
cancer, adenomatous polyps and recessive inheritance is undoubtedly largely explained by 
CMMR-D, but new APC mutations (as seen in FAP, q.v. 2.2.1) are also possible.   
 2.2 Polyposes 
2.2.1 Familial Adenomatous Polyposis (FAP) 
FAP is the archetypal cancer predisposition syndrome, of singular importance in that it was one of 
the first human Mendelian genetic conditions to be identified, and was instrumental both in the 
concept of cancer arising from premalignant lesions (the adenoma-carcinoma sequence) and the 
development by Dukes of one of the first systems for cancer staging.  It is a multisystem disorder 
due to dominantly inherited mutations in the APC gene, with a prevalence of 1:8500.  The 
mutations are invariably protein truncating, causing the loss of beta-catenin binding sites in the 
expressed APC protein, with consequent dysregulation of wnt-signalling resulting in cellular 
dysplasia.(Fig. 3)  Up to 10% of cases may be due to de novo mutations, but some of these are 
undiagnosed MAP.(see 2.3.3).  The established adenomas and carcinomas are otherwise 
unremarkable, and there are no specific tests for FAP that can be carried out on them.  However, 
multiple monocryptal adenomas are considered a helpful diagnostic feature. 
Fig. 3 Sections of mouse small intestine 
Hundreds to thousands of colorectal adenomas develop in teenage, resulting in an almost 100% 
lifetime risk of colorectal cancer if prophylactic total colectomy is not performed, usually in late 
teenage.  Untreated, the average age of bowel cancer is 42y, but in families with thousands of 
polyps it is 29y.  Small bowel adenomas also arise, characteristically in the duodenum and are an 
especial clinical problem, because prophylactic surgery is not possible and duodenal cancer 
carries a poor prognosis: indeed it is now one of the leading causes of death in FAP.  Adenomas 
also develop in small bowel used to construct pouches post-colectomy.  Rectal polyps arising after 
total colectomy and ileorectal anastomosis are managed until the risk of rectal cancer in the 5th 
decade of life becomes significant and resection is performed. 
Desmoid tumours are another major cause of mortality and morbidity: they are histologically benign 
but clinically malignant.  They can and do occur sporadically, but in FAP are more common intra-
abdominally and around the trunk.  They are indolent, unresponsive to chemotherapy, encroach on 
vital structures like small bowel and ureters and surgery is problematic, indeed colectomy may 
actually provoke or stimulate precursor lesions in the mesentery.[19] 
Benign gastric fundic gland polyps are commonly seen in the stomach with occasional adenomas.  
Hepatoblastoma is seen in children, and hepatobiliary cancers in adults.  Brain (usually 
medulloblastoma) and papillary thyroid carcinomas also occur at low frequency (1-3%).  
Epidermoid (sebaceous) and odontoid cysts are common as are osteomas, adrenal adenomas and 
supernumerary teeth.  The constellation of colonic polyposis and extracolonic features was 
described by Gardner in the 1950’s, but close examination reveals most if not all FAP patients 
have these features, so it is an obsolete term. 
2.2.2  Attenuated FAP (AFAP) 
Some families with mutations in particular parts of the APC gene develop fewer than 100 colorectal 
adenomas, the threshold for classical FAP, and some individuals may not develop any polyps.  
The average age of cancer is 55y.  Other FAP-related features may not be seen, but some families 
can have a very high risk of desmoids.  Only about 10% of individuals with <100 adenomas have a 
mutation in APC.  As with FAP, there are no specific tumour tests for AFAP. 
2.2.3  MUTYH-associated polyposis (MAP) 
In 2003, recessive inheritance of mutations in a DNA repair enzyme called mutY homologue 
(MUTYH) was shown to cause adenomatous polyposis.  Like other classic autosomal recessive 
DNA repair disorders, individuals inherit MUTYH mutations from both parents, who themselves are 
not affected.  The phenotype overlaps with FAP and AFAP: patients develop up to a few hundred 
adenomas, but may not develop any, although they may still develop cancer.  About 25% of those 
with >9 adenomas and without a dominant family history have MAP, as do 5% of those with 3 to 
100 adenomas otherwise unselected.  Upper GI polyposis certainly occurs, with risk of cancer, and 
the rate of extra-intestinal cancers is modestly increased, in particular ovary, bladder and skin, but 
others may be involved.  There are no specific tumour tests for MAP, but genetic testing for MAP is 
simplified by only needing to test for common mutations in the first instance, and so is relatively 
quick and inexpensive.   
The loss of oxidative DNA damage repair in MAP results in innumerable mutations all over the 
genome, mostly G>T changes.  Occasionally this may manifest as microsatellite instability (MSI) 
and thus make it appear as if the tumour might be due to Lynch syndrome, but a multiplicity of 
adenomas will be the clue that something other than LS is the cause.(see also 2.2.4) 
2.2.4  Polymerase-associated Polyposis (PAP) 
This condition has only been recently described and is being elucidated.  Families with LS-like 
family histories, e.g. colorectal and endometrial cancers, plus multiple colorectal adenomas 
(variable, but up to approximately 50) have been found to have constitutional mutations affecting 
the proof-reading domains of DNA polymerases (POLD1 and POLE).  As yet there are no specific 
tests for PAP such as IHC for the respective polymerase proteins.  Hence, diagnosis involves 
testing for Lynch and MAP with negative findings, including generally MSS tumours, and then 
testing the POLD1 and POLE genes.  However, PAP-related tumours accumulate innumerable 
point mutations all over the genome, so just as in MAP their tumours may occasionally show MSI, 
suggesting LS.  Hence, it is important to consider the overall pattern of findings in a family in 
conjunction with genetics colleagues.  
 
2.2.5  Serrated Polyposis Syndrome (SPS) 
In SPS (previously known as Hyperplastic Polyposis Syndrome) multiple hyperplastic or serrated 
lesions (mostly hyperplastic polyps, but also many sessile serrated lesions/polyps/adenomas with 
a few serrated adenomas) are found in the large bowel, and there is an increased risk of bowel 
cancer.(Fig. 4) 
Fig. 4  Tumours seen in Serrated Polyposis Syndrome.  
 
If a patient fulfils any of the WHO criteria a diagnosis of SPS is made [20]:- 
A At least five serrated lesions proximal to the sigmoid colon, two of which are greater than 
10 mm in diameter, or 
B Any number of serrated lesions occurring proximal to the sigmoid colon in an individual who 
has a first-degree relative with serrated polyposis, or 
C More than 20 serrated lesions of any size distributed throughout the colon. 
SPS shows a strong familial effect: first-degree relatives have a 5-fold increased risk of CRC.  It 
appears more common in those of European descent, but the genetics remain to be determined.  
Smoking is associated with greater numbers of hyperplastic, but especially serrated lesions.  CRC 
of serrated origin may have MSI, and so young onset CRCs arising in the setting of serrated 
polyposis can masquerade as a ‘Lynch cancer’ until the polyp phenotype is appreciated or a BRAF 
V600E mutation is found.[21] 
 
2.2.6  Peutz-Jeghers Polyposis (PJS) 
Peutz-Jeghers syndrome is due to inherited mutations in STK11 (LKB1).  The histology of PJS 
polyps is characteristic and diagnostic, consisting of branched or frond-like patterns of the 
muscularis mucosae smooth muscle, termed arborization.(Fig. 5)  Cystic gland dilatation is 
observed, which may extend into the sub-mucosa and muscularis propria.  Juvenile polyps, in 
contrast, have a lamina propria mostly lacking smooth muscle, but nonetheless the two types are 
often confused.  Small bowel JPS polyps can exhibit ‘pseudoinvasion’ (epithelial misplacement) 
which can be mistaken for invasive carcinoma.  Histological review should therefore be considered. 
Fig. 5  Peutz-Jeghers polyp 
PJS polyps typically affect the small bowel, leading to intussucception and obstruction.  Few, if 
any, patients will get into their third decade without at least one laparotomy.  It is therefore 
important that the condition be recognised and treated at expert centres which can offer the 
appropriate specialist care such as resecting as many polyps as possible at one operation.  PJS 
patients are at risk of a variety of malignancies, especially of the GI tract, including pancreas, 
breast, uterine, and gonadal tumours with a risk of any cancer by age of 70 y of around 90%.  The 
typical perioral freckling is also found around other centre line orifices but usually fades after the 
age of 20y.   
In a single individual, a clinical diagnosis of PJS may be made when any one of the following is 
present [22]: 
1. Two or more histologically confirmed PJ polyps. 
2. Any number of PJ polyps detected in one individual who has a family history of PJS in close 
relative(s). 
3. Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in 
close relative(s). 
4. Any number of PJ polyps in an individual who also has characteristic mucocutaneous 
pigmentation. 
 
2.2.7  Juvenile Polyposis Syndrome (JPS) 
Juvenile polyps occur sporadically in childhood.  They are delicate structures that are prone to 
haemorrhage, prolapse, and auto-amputation, so they not uncommonly cause anaemia and being 
fragile they are typically inflamed and thus are frequently misdiagnosed as inflammatory 
polyps.(Fig. 6)  They occur throughout the colorectum, albeit with a slight preponderance in the 
rectosigmoid colon.  However, there is a group of individuals who develop multiple juvenile polyps, 
often with a family history of the same or bowel cancer – this is familial juvenile polyposis 
syndrome (JPS), due to either SMAD4 or BMPR1A mutations.  JPS is an autosomal dominant 
(AD) condition with variable penetrance, associated with an increased risk of colorectal cancer 
(CRC 10–38%) and of gastric and duodenal cancer (15–21%).  Adenomatous change can be 
found in juvenile polyps and this may account for their malignant potential.[23]   
Fig. 6  Juvenile polyp 
In the absence of features suggesting Cowden syndrome, JPS is diagnosed when there are:- 
• >5 juvenile polyps in the colon or rectum, or 
• Juvenile polyps in other parts of the GI tract, or 
• Any number of juvenile polyps and a positive family history. 
 
2.2.8  Hereditary Mixed Polyposis Syndrome (HMPS) 
This is a rare condition characterized by the development of a mixture of colorectal polyps in the 
same individual, including adenomas and serrated lesions, juvenile and JPS-like polyps, and mixed 
polyps with combinations of these features, e.g. adenomas with serrated features, hyperplastic 
polyps with adenomatous change, and juvenile polyps with hyperplastic or dysplastic features.(Fig. 
7)  It is due to abnormal expression of very large amounts of Gremlin, a protein involved in 
APC/wnt regulation in crypts in the bowel mucosa.  A mutation outside of the GREM1 gene, but 
close to it, causes upregulated ectopic expression.  Thus, HMPS has a unique mechanism – the 
affected protein is not in itself mutant, rather its abnormal pattern of expression leads to dysplasia 
and malignancy.  The original family affected with HMPS is of Ashkenazi Jewish origin, but 
mutations affecting Gremlin expression may well have occurred in other families, and there is 
evidence that common variants near GREM1 influence CRC risk in the general population.[24] 
Fig. 7  Examples of polyps seen in HMPS 
2.2.9  Cowden’s Syndrome (CS) 
CS is due to constitutional PTEN mutations and the overarching term ‘PTEN Hamartoma Tumour 
Syndrome’ is proposed, because phenotypically overlapping conditions, such as Bannayan-Riley-
Ruvalcaba, PTEN-related Proteus and Proteus-like syndromes are also caused by PTEN 
mutations, indeed often the exact same mutations as cause CS.[25]  Adenomas, various 
hamartomas and other lesions, including lipomas, fibromas and characteristic ganglioneuromas 
are described in the large bowel in CS patients.(Fig. 8)  The lifetime risk of CRC in CS appears to 
be modestly increased at about 9%. 
Fig. 8 Cowden ganglioneuroma 
Practice points 
• A multidisciplinary team approach should be taken to the diagnosis of hereditary GI cancer, 
and Lynch syndrome in particular: a familial pattern in tumour and genetic findings may be 
evident when individual findings are less obviously significant. 
• Give at least an approximate numerical estimate of polyp numbers, e.g. “<10” or “20-50”: 
use of the word ‘multiple’ without quantification is ambiguous and to be discouraged. 
• If assessing DNA MMR by immunohistochemistry participate in EQA and test all four 
markers (MSH2, MLH1, MSH6 and PMS2). 
• Abnormality of DNA MMR may be manifest as abnormal rather than simple loss of 
expression: e.g. patchy/weak or cytoplasmic and/or loss of nuclear staining. 
• Patterns of MMR IHC abnormality are a guide to, but not an absolute indicator of the 
underlying genetic defect.   
• Beware!  Both MSI and MMR IHC testing are less sensitive when used on benign tumours, 
cancers at sites other than the colon, and when mutations in the MSH6 and PMS2 genes 
are the underlying cause.  One may be abnormal when the other is not. 
• Juvenile polyps are often misdiagnosed as “inflammatory”; juvenile and Peutz-Jeghers 
polyps are commonly confused. 
• Young onset colorectal cancers arising in serrated polyps or serrated polyposis syndrome 
may masquerade as LS, because of the loss of MMR: take note of associated polyps. 
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